奈非那韦联合同步放化疗治疗不可切除IIIA/IIIB期非小细胞肺癌的1/2期试验临床结局
该前瞻性单中心单臂1/2期试验纳入35例不可切除IIIA/IIIB期非小细胞肺癌患者,评估口服HIV蛋白酶抑制剂甲磺酸奈非那韦联合同步放化疗的毒性、最大耐受剂量及2期推荐剂量,并估计客观缓解率、局部/远处失败率和总生存。结果显示无剂量限制性毒性,客观缓解率94%,中位总生存41.1个月,提示该方案毒性可接受且疗效有前景。
要点
- 奈非那韦联合同步放化疗未观察到剂量限制性毒性,无4级及以上非血液学毒性。
- 33例可评估患者客观缓解率达94%(95%CI 86%-100%)。
- 中位总生存41.1个月,5年总生存率37.1%,局部失败累积发生率39%。
核心结论
- 奈非那韦联合同步放化疗在不可切除局部晚期非小细胞肺癌中毒性可接受,客观缓解率、局部失败率、无进展生存和总生存结果有前景,提示奈非那韦可能增强标准放化疗疗效,需随机3期试验进一步验证。
研究设计与样本
- 前瞻性、开放标签、单组、单中心1/2期试验,纳入35例18至89岁活检确诊的不可切除IIIA/IIIB期局部晚期非小细胞肺癌患者,研究时间为2007年6月29日至2012年2月22日,分析日期为2017年5月9日,中位随访6.8年。
- 干预为口服甲磺酸奈非那韦625 mg每日两次或1250 mg每日两次,在同步放化疗前7至14天开始并持续至放化疗期间。
主要发现
- 35例患者中女性16例、男性19例,中位年龄60岁(范围39-79岁),5例接受625 mg每日两次,30例接受1250 mg每日两次。
- 未观察到剂量限制性毒性,也未观察到4级及以上非血液学毒性。
- 35例中33例有可评估的治疗后CT扫描,客观缓解率为94%(31/33;95%CI 86%-100%)。
- 局部失败累积发生率为39%(95%CI 30.5%-47.5%),中位无进展生存期为11.7个月(95%CI 6.2-17.1个月)。
- 全部患者中位总生存期为41.1个月(95%CI 19.0-63.1个月),5年总生存率均值(标准误)为37.1%(8.2%)。
关键数值与推荐
- 剂量限制性毒性:未观察到。
- 4级及以上非血液学毒性:未观察到。
- 客观缓解率:94%(31/33;95%CI 86%-100%)。
- 局部失败累积发生率:39%(95%CI 30.5%-47.5%)。
- 中位无进展生存期:11.7个月(95%CI 6.2-17.1个月);中位总生存期:41.1个月(95%CI 19.0-63.1个月);5年总生存率均值(标准误):37.1%(8.2%)。
临床怎么用
- 该1/2期试验提示奈非那韦联合同步放化疗在不可切除局部晚期非小细胞肺癌中毒性可接受且疗效信号积极,但目前证据限于单中心单臂小样本,尚不能作为标准临床推荐,需等待随机3期试验验证。
局限性
- 单中心、单组、开放标签设计,样本量35例,无随机对照,结论需随机3期试验进一步确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Local failure after chemoradiotherapy (CT-RT) significantly contributes to mortality in patients with locally advanced non-small cell lung cancer (LA-NSCLC). One approach to improve local control is through targeted radiosensitization of the tumor. OBJECTIVE: To evaluate the dose-limiting toxic effects, maximally tolerated dose, and recommended phase 2 dose of the protease inhibitor nelfinavir mesylate, administered concurrently with CT-RT in patients with LA-NSCLC, and, in the phase 2 portion of the study, to estimate the objective response rate, local and distant failure rates, and overall survival. DESIGN, SETTING, AND PARTICIPANTS: This prospective, open-label, single-group, single-institution phase 1/2 trial tested the oral protease inhibitor nelfinavir in combination with concurrent CT-RT in 35 patients aged 18 to 89 years with biopsy-confirmed unresectable stage IIIA/IIIB LA-NSCLC and a minimum Karnofsky performance status from June 29, 2007, to February 22, 2012, with an analysis date of May 9, 2017. Median follow-up for all patients was 6.8 years, with a minimum 5 years of follow-up for all survivors. INTERVENTIONS: Oral nelfinavir mesylate, 625 mg, twice daily or 1250 mg, twice daily was administered for 7 to 14 days before and during concurrent CT-RT. MAIN OUTCOMES AND MEASURES: Graded toxic effects, overall survival, local failure, distant failure, objective response rate, and progression-free survival as measured by Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Thirty-five patients (16 women and 19 men; median age, 60 years [range, 39-79 years]) enrolled and met protocol-specified criteria for adherence, with 5 at a dose of 625 mg twice daily and 30 at a dose of 1250 mg twice daily. No dose-limiting toxic effects were observed. No grade 4 or higher nonhematologic toxic effects were observed. Thirty-three of the 35 patients had evaluable posttreatment computed tomographic scans, with an objective response rate of 94% (31 of 33; 95% CI, 86%-100%). The cumulative incidence of local failure was 39% (95% CI, 30.5%-47.5%). Median progression-free survival was 11.7 months (95% CI, 6.2-17.1 months). Median overall survival for all patients was 41.1 months (95% CI, 19.0-63.1 months); the 5-year mean (SE) overall survival rate was 37.1% (8.2%). CONCLUSIONS AND RELEVANCE: This study suggests that nelfinavir administered with concurrent CT-RT is associated with acceptable toxic effects and a promising objective response rate, local failure, progression-free survival, and overall survival in unresectable LA-NSCLC. These data suggest that nelfinavir may enhance the efficacy of standard CT-RT in this disease. Additional testing in the randomized phase 3 setting should be conducted to establish the improvement associated with nelfinavir with concurrent CT-RT. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00589056.
引用
- Rengan R, Mick R, Pryma DA, et al. Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial. JAMA Oncol. 2019. PMID: 31436839. doi:10.1001/jamaoncol.2019.2095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。